Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Biotech Startup

Section: Biopharma Insights     View all sections


11 Inspiring Women Advancing Artificial Intelligence In Life Sciences

   by BiopharmaTrend    2984
11 Inspiring Women Advancing Artificial Intelligence In Life Sciences

In this post, we decided to highlight eleven entrepreneurial women, leading the way in applying advanced computational technologies, such as machine learning (ML), deep learning (DL), and other artificial intelligence (AI) components, for tackling some of the hardest challenges of science -- in drug discovery and healthcare. This list is composed in alphabetical order. 

[Interview] Building Canada’s Life Sciences Community and Thinking Global

   by Andrii Buvailo    380
[Interview] Building Canada’s Life Sciences Community and Thinking Global

Canada has a firm place in the global life sciences ecosystem, being the tenth largest market for pharmaceutical sales, and home to America’s second-largest life sciences corridor. The country has a long history of life science research, including the creation of the first pacemaker and discovery of stem cells. 

According to a survey conducted by BIOTECanada and Deloitte in 2018, conducted in 2018, the Canadian life sciences sector includes many early-stage companies with substantial growth potential -- 67% of responders identified themselves as being in the discovery or emerging phase of development in 2017. Surveyed organizations reported intentions to raise additional capital in the coming years and reported access to capital as the primary issue in the life sciences sector in Canada.

Top Companies At The Forefront Of RNA Therapeutics Development

   by Irina Bilous    1278
Top Companies At The Forefront Of RNA Therapeutics Development

Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs in the field of RNA-targeting medicines, primarily falling into the following two categories: antisense oligonucleotides (ASO), and RNA interference (RNAi) technologies. (another promising approach, dealing with editing RNA itself by ADAR enzymes, is not covered in this post). 

The Overview of AI in Drug Discovery in 2019: The “Proof-of-concept Year”

   by Andrii Buvailo    5310
The Overview of AI in Drug Discovery in 2019: The “Proof-of-concept Year”

The race for adopting new machine learning (ML), deep learning (DL) and related technologies (for simplicity -- “artificial intelligence”/”AI”) keeps rapidly unfolding in the pharmaceutical industry, albeit with varying rate of progress across different use cases

Let’s review retrospectively some of the key developments in the drug discovery area in 2019 and see how they characterize the current state of AI in the pharmaceutical industry (“hype vs reality”). Note, that I do not cover the healthcare sector in this post (diagnostics, medical applications of AI, digital health etc) -- those will be discussed in one of the future posts.